PT-141
US$ 23.55
bpc-157 human clinical trials status fda warning Legal Status: Regulations and Compounding BPC 157 Banned: Key Facts
Description
Sustained focal effects of low-dose intramuscular succinylcholine
This comprehensive analysis examines the clinical trial evidence for AOD-9604s safety profile, including participant numbers, study designs, reported adverse effects, metabolic safety markers, immunogenicity data, and how this peptides safety characteristics compare to related therapies
Severe GI reactions (peptic ulcer, GI bleeding, and GI perforation) occurred in 0.4% to 4.6% of patients without a history of a peptic ulcer or bleed and in 2.1% to 15.4% of patients with a history of a peptic ulcer or bleed
BMJ Open ., 2020 Aug 20
